

10681711

=> d his

(FILE 'HOME' ENTERED AT 18:50:03 ON 11 MAY 2004)

FILE 'REGISTRY' ENTERED AT 18:50:14 ON 11 MAY 2004

L1 STRUCTURE UPLOADED

L2 5 S L1

L3 95 S L1 SSS FULL

FILE 'CAPLUS' ENTERED AT 18:51:01 ON 11 MAY 2004

L4 10 S L3

=> d 1-10 bib abs hitstr

L4 ANSWER 1 OF 10 CAPLUS COPYRIGHT 2004 ACS on STN

AN 2004:331904 CAPLUS

TI Immune response modifier-antigen immunostimulatory compositions and methods of stimulating an immune response

IN Kedl, Ross M.; Griesgraber, George W.; Zarraga, Isidro Angelo E.

PA 3M Innovative Properties Company, USA

SO PCT Int. Appl., 56 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004032829	A2	20040422	WO 2003-US25523	20030814
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				

PRAI US 2002-403846P P 20020815

AB The invention provides immunostimulatory compns. that include an immune response modifier (IRM) portion (e.g. an imidazoquinoline derivative) paired with an antigenic portion (e.g. ovalbumin). Preparation of IRM derivs., e.g. I, is included.

IT INDEXING IN PROGRESS



IT **680987-05-7P 680987-06-8P**

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(immune response modifier-antigen immunostimulatory compns., preparation, and methods use)

RN 680987-05-7 CAPLUS

CN INDEX NAME NOT YET ASSIGNED



chain nodes :

14 15 16 17 20 21 24 25 27 29 30 31

ring nodes :

1 2 3 4 5 6 7 8 9 10 11 12 13

chain bonds :

4-14 13-15 15-16 16-17 17-21 20-21 24-25 24-27 29-30 30-31

ring bonds :

1-2 1-6 1-7 2-3 2-10 3-4 4-5 5-6 5-11 6-13 7-8 8-9 9-10 11-12 12-13

exact/norm bonds :

1-7 2-10 4-14 5-11 6-13 7-8 8-9 9-10 11-12 12-13 13-15 15-16 16-17 17-21
20-21 24-25 24-27 29-30 30-31

normalized bonds :

1-2 1-6 2-3 3-4 4-5 5-6



G1:S,O

G2:O,S,N


G3:[*1],[*2]

Match level :

1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:Atom 11:Atom
12:Atom 13:Atom 14:CLASS 15:CLASS 16:CLASS 17:CLASS 20:CLASS 21:CLASS 24:CLASS
25:CLASS 27:CLASS 29:CLASS 30:CLASS 31:CLASS



RN 680987-06-8 CAPLUS
CN INDEX NAME NOT YET ASSIGNED




IT 436856-98-3P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(immune response modifier-antigen immunostimulatory compns., preparation, and methods use)

RN 436856-98-3 CAPLUS

Carbamic acid, [2-[2-[4-amino-2-(2-methoxyethyl)-1H-imidazo[4,5-c]quinolin-1-yl]ethoxy]ethyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



10681711



L4 ANSWER 2 OF 10 CAPLUS COPYRIGHT 2004 ACS on STN
 AN 2004:291951 CAPLUS
 DN 140:321358
 TI Preparation of imidazo[4,5-c]quinoline dimers as immune response modifiers
 IN Griesgraber, George W.
 PA 3M Innovative Properties Company, USA
 SO PCT Int. Appl., 71 pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004028539	A2	20040408	WO 2003-US30372	20030925
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
PRAI US 2002-413848P	P	20020926		

GI



II

AB Title compds. I [wherein R2 = H, (un)substituted alkyl, alkenyl, (hetero)aryl, etc.; R3, R4 = independently H, halo, alkyloxy, alkenyl, alkylthio, amino, or R3R4 = (un)substituted (hetero)aryl ring; A = alkylene, alkenylene, alkynylene, etc.; and pharmaceutically acceptable

salts thereof], and analogs (4 addnl. Markush structures), were prepared as immune response modifiers. For example, reaction of 1-(4-aminobutyl)-2-butyl-1H-imidazo[4,5-c]quinolin-4-amine with 1,3-phenylene diisocyanate in CH₂Cl₂ under N₂ at r.t., gave II as a white solid. II stimulated interferon α and tumor necrosis factor (TNF- α) biosynthesis in human blood cell at concentration of less than or equal to 10 μ M. Thus, I and their pharmaceutical comps. induce cytokines biosynthesis and are useful in the treatment of a variety of conditions including viral diseases and neoplastic diseases.

IT **677354-10-8P 677354-11-9P**


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of imidazo[4,5-c]quinoline dimers as immune response modifiers)


RN 677354-10-8 CAPLUS

CN 1,3-Benzenedicarboxamide, N,N'-bis[2-[2-[4-amino-2-(2-methoxyethyl)-1H-imidazo[4,5-c]quinolin-1-yl]ethoxy]ethyl]- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 677354-11-9 CAPLUS

CN 16-Oxa-2,11,13-triazaoctadecanamide, 18-[4-amino-2-(2-methoxyethyl)-1H-imidazo[4,5-c]quinolin-1-yl]-N-[2-[2-[4-amino-2-(2-methoxyethyl)-1H-imidazo[4,5-c]quinolin-1-yl]ethoxy]ethyl]-12-oxo- (9CI) (CA INDEX NAME)



L4 ANSWER 3 OF 10 CAPLUS COPYRIGHT 2004 ACS on STN
 AN 2003:892446 CAPLUS
 DN 139:364934
 TI Preparation of aryl ether substituted imidazoquinolines as immune response modifiers
 IN Heppner, Philip D.; Charles, Leslie J.; Dellaria, Joseph F.; Merrill, Bryon A.; Mickelson, John W.
 PA 3M Innovative Properties Co., USA
 SO U.S. Pat. Appl. Publ., 97 pp., Cont.-in-part of U.S. Ser. No. 13,202.
 CODEN: USXXCO
 DT Patent
 LA English
 FAN.CNT 11

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 2003212092	A1	20031113	US 2002-165750	20020607
	US 6677348	B2	20040113		
	US 2003212091	A1	20031113	US 2001-13202	20011206
	US 6670372	B2	20031230		
	US 2004072858	A1	20040415	US 2003-675833	20030930
PRAI	US 2000-254218P	P	20001208		
	US 2001-13202	A2	20011206		
	US 2001-11921	A1	20011206		
OS	MARPAT 139:364934				
GI					



AB The title compds. [I; X = (CH₂)₂, CH₂EtCH₂, etc.; R₁ = alkenyl, aryl, R₄-aryl; R₂ = H, alkyl, alkenyl, etc.; R₄ = alkyl, alkenyl which may be interrupted by one or more O atoms; R₃ = H, alkyl; n = 0-4; R = alkyl, alkoxy, OH, etc.] that contain ether and aryl or alkenyl functionality at the 1-position, and are useful as immune response modifiers, were prepared E.g., a multi-step synthesis of I [X = (CH₂)₂; R₁ = CH₂C.tplbond.CH; R₂ = H; n = 0] which showed the lowest effective concentration of 0.12 μM and 1.11 μM to induce biosynthesis of interferon α and TNFα in human cells, resp., was given. The compds. I can induce the biosynthesis of various cytokines and are useful in the treatment of a variety of

10681711

conditions including viral diseases and neoplastic diseases. The pharmaceutical composition comprising the compound I is claimed.

IT 437601-48-4P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of aryl ether substituted imidazoquinolines as immune response modifiers)


RN 437601-48-4 CAPLUS

CN Acetic acid, [2-(4-amino-1H-imidazo[4,5-c]quinolin-1-yl)butoxy]-, methyl ester, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 436855-99-1


CMF C17 H20 N4 O3



CM 2

CRN 76-05-1

CMF C2 H F3 O2



L4 ANSWER 4 OF 10 CAPLUS COPYRIGHT 2004 ACS on STN

AN 2003:777397 CAPLUS

DN 139:292250

TI Preparation of amido ether substituted imidazoquinolines as immune response modifiers

IN Crooks, Stephen L.; Griesgraber, George W.; Heppner, Philip D.; Merrill, Bryon A.

PA 3M Innovative Properties Co., USA

SO U.S. Pat. Appl. Publ., 50 pp., Cont.-in-part of U.S. Ser. No. 11,670.

CODEN: USXXCO

DT Patent


LA English

FAN.CNT 11

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 2003187016	A1	20031002	US 2002-165449	20020607
	US 6664265	B2	20031216		
	US 2003096835	A1	20030522	US 2001-11670	20011206
	US 6660747	B2	20031209		
	US 2004072858	A1	20040415	US 2003-675833	20030930
	US 2004067975	A1	20040408	US 2003-681711	20031007
PRAI	US 2000-254218P	P	20001208		
	US 2001-11670	A2	20011206		
	US 2001-11921	A1	20011206		
	US 2002-165449	A1	20020607		

OS MARPAT 139:292250

GI



AB The title compds. [I; X = (CH₂)₂, CH(Et)CH₂, etc.; R₁ = (CH₂)₄CONMePh, (CH₂)₂NHCO(cyclohexyl), (CH₂)₂NHCO(1-naphthyl), etc.; R₂ = H, alkyl, alkenyl, etc.; R = alkyl, alkoxy, OH, halo, CF₃; n = 0-4] and their pharmaceutically acceptable salts that contain ether and amide functionality at the 1-position, and are useful as immune response modifiers, were prepared. Thus, reacting 2-(1H-imidazo[4,5-c]quinolin-1-yl)ethanol with 5-bromo-N-methyl-N-phenylpentamide followed by treatment of the resulting N-oxide with trichloroacetyl isocyanate in CH₂Cl₂, and then treating the intermediate with NaOMe in MeOH afforded I [X = (CH₂)₂; R₁ = (CH₂)₄CONMePh; R₂ = H; n = 0] which showed interferon α induction in human cells at 3.33 μ M. The compds. I and compns. comprising I can induce the biosynthesis of various cytokines, and are useful in the treatment of a variety of conditions, including viral diseases and neoplastic diseases.


IT 436855-82-2P 436855-84-4P 436855-87-7P
 436855-91-3P 436855-95-7P 436855-97-9P
 436855-99-1P 436856-00-7P 436856-01-8P
 436856-02-9P 436856-03-0P 436856-04-1P
 436856-05-2P 436856-06-3P 436856-07-4P
 436856-08-5P 436856-09-6P 436856-10-9P
 436856-11-0P 436856-12-1P 436856-13-2P
 436856-14-3P 436856-15-4P 436856-16-5P
 436856-17-6P 436856-18-7P 436856-19-8P
 436856-42-7P 436856-44-9P 436856-46-1P
 436856-48-3P 436856-50-7P 436856-52-9P
 436856-54-1P 436856-56-3P 436856-58-5P
 436856-60-9P 436856-62-1P 436856-64-3P
 436856-66-5P 436856-68-7P 436856-70-1P
 608512-33-0P 608512-34-1P 608512-35-2P
 608512-36-3P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of amido ether substituted imidazoquinolines as immune response modifiers)

RN 436855-82-2 CAPLUS


CN Benzamide, N-[2-[2-[4-amino-2-(2-methoxyethyl)-1H-imidazo[4,5-c]quinolin-1-yl]ethoxy]ethyl]- (9CI) (CA INDEX NAME)



RN 436855-84-4 CAPLUS


CN Benzamide, N-[2-[2-[4-amino-6,7,8,9-tetrahydro-2-(2-methoxyethyl)-1H-imidazo[4,5-c]quinolin-1-yl]ethoxy]ethyl]- (9CI) (CA INDEX NAME)

10681711




RN 436855-87-7 CAPLUS

CN Benzamide, N-[2-[2-[4-amino-2-(2-methoxyethyl)-1H-imidazo[4,5-c]quinolin-1-yl]ethoxy]ethyl]-N-methyl- (9CI) (CA INDEX NAME)




RN 436855-91-3 CAPLUS

CN Benzamide, N-[2-[2-[4-amino-6,7,8,9-tetrahydro-2-(2-methoxyethyl)-1H-imidazo[4,5-c]quinolin-1-yl]ethoxy]ethyl]-N-methyl- (9CI) (CA INDEX NAME)



RN 436855-95-7 CAPLUS


CN Pentanamide, 5-[2-(4-amino-1H-imidazo[4,5-c]quinolin-1-yl)ethoxy]-N-methyl-N-phenyl- (9CI) (CA INDEX NAME)




RN 436855-97-9 CAPLUS

CN Pentanamide, 5-[2-(4-amino-1H-imidazo[4,5-c]quinolin-1-yl)ethoxy]-N-butyl-N-phenyl- (9CI) (CA INDEX NAME)

10681711




RN 436855-99-1 CAPLUS
CN Acetic acid, [2-(4-amino-1H-imidazo[4,5-c]quinolin-1-yl)butoxy]-, methyl ester (9CI) (CA INDEX NAME)



RN 436856-00-7 CAPLUS
CN Cyclopropanecarboxamide, N-[2-[2-(4-amino-2-butyl-1H-imidazo[4,5-c]quinolin-1-yl)ethoxy]ethyl]- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A



RN 436856-01-8 CAPLUS
CN Pentanamide, N-[2-[2-(4-amino-2-butyl-1H-imidazo[4,5-c]quinolin-1-yl)ethoxy]ethyl]- (9CI) (CA INDEX NAME)


10681711




RN 436856-02-9 CAPLUS

CN Cyclopentanecarboxamide, N-[2-[2-(4-amino-2-butyl-1H-imidazo[4,5-c]quinolin-1-yl)ethoxy]ethyl]- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A



RN 436856-03-0 CAPLUS

CN Benzamide, N-[2-[2-(4-amino-2-butyl-1H-imidazo[4,5-c]quinolin-1-yl)ethoxy]ethyl]- (9CI) (CA INDEX NAME)




RN 436856-04-1 CAPLUS


10681711

CN Cyclohexanecarboxamide, N-[2-[2-(4-amino-2-butyl-1H-imidazo[4,5-c]quinolin-1-yl)ethoxy]ethyl]- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A





RN 436856-05-2 CAPLUS

CN Benzeneacetamide, N-[2-[2-(4-amino-2-butyl-1H-imidazo[4,5-c]quinolin-1-yl)ethoxy]ethyl]- (9CI) (CA INDEX NAME)





RN 436856-06-3 CAPLUS

CN Benzamide, N-[2-[2-(4-amino-2-butyl-1H-imidazo[4,5-c]quinolin-1-yl)ethoxy]ethyl]-4-fluoro- (9CI) (CA INDEX NAME)





RN 436856-07-4 CAPLUS
 CN 2-Thiopheneacetamide, N-[2-[2-(4-amino-2-butyl-1H-imidazo[4,5-c]quinolin-1-yl)ethoxy]ethyl]- (9CI) (CA INDEX NAME)







RN 436856-08-5 CAPLUS
 CN Benzamide, N-[2-[2-(4-amino-2-butyl-1H-imidazo[4,5-c]quinolin-1-yl)ethoxy]ethyl]-4-cyano- (9CI) (CA INDEX NAME)




RN 436856-09-6 CAPLUS
 CN Benzamide, N-[2-[2-(4-amino-2-butyl-1H-imidazo[4,5-c]quinolin-1-yl)ethoxy]ethyl]-3-cyano- (9CI) (CA INDEX NAME)





RN 436856-10-9 CAPLUS

CN Benzenepropanamide, N-[2-[2-(4-amino-2-butyl-1H-imidazo[4,5-c]quinolin-1-yl)ethoxy]ethyl]- (9CI) (CA INDEX NAME)




RN 436856-11-0 CAPLUS

CN Benzanamide, N-[2-[2-(4-amino-2-butyl-1H-imidazo[4,5-c]quinolin-1-yl)ethoxy]ethyl]-3-methoxy- (9CI) (CA INDEX NAME)




RN 436856-12-1 CAPLUS
 CN Benzamide, N-[2-(2-(4-amino-2-butyl-1H-imidazo[4,5-c]quinolin-1-yl)ethoxy)ethyl]-4-methoxy- (9CI) (CA INDEX NAME)




10681711

PAGE 2-A




RN 436856-13-2 CAPLUS
CN 3-Pyridinecarboxamide, N-[2-[2-(4-amino-2-butyl-1H-imidazo[4,5-c]quinolin-1-yl)ethoxy]ethyl]-6-chloro- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A



RN 436856-14-3 CAPLUS
CN Cyclopropanecarboxamide, N-[2-[2-(4-amino-2-butyl-1H-imidazo[4,5-c]quinolin-1-yl)ethoxy]ethyl]-2-phenyl-, (1R,2R)-rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.

10681711



RN 436856-15-4 CAPLUS


CN Acetamide, N-[2-[2-(4-amino-2-butyl-1H-imidazo[4,5-c]quinolin-1-yl)ethoxy]ethyl]-2-(phenylmethoxy)- (9CI) (CA INDEX NAME)




RN 436856-16-5 CAPLUS



CN 1-Naphthalenecarboxamide, N-[2-[2-(4-amino-2-butyl-1H-imidazo[4,5-c]quinolin-1-yl)ethoxy]ethyl]- (9CI) (CA INDEX NAME)

PAGE 1-A








RN 436856-17-6 CAPLUS
 CN Benzamide, N-[2-[2-(4-amino-2-butyl-1H-imidazo[4,5-c]quinolin-1-yl)ethoxy]ethyl]-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 436856-18-7 CAPLUS
 CN Benzamide, N-[2-[2-(4-amino-2-butyl-1H-imidazo[4,5-c]quinolin-1-yl)ethoxy]ethyl]-4-(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 436856-19-8 CAPLUS
 CN Benzamide, N-[2-[2-(4-amino-2-butyl-1H-imidazo[4,5-c]quinolin-1-yl)ethoxy]ethyl]-4-(trifluoromethoxy)- (9CI) (CA INDEX NAME)







RN 436856-42-7 CAPLUS
 CN Pentanamide, N-[2-[2-(4-amino-1H-imidazo[4,5-c]quinolin-1-yl)ethoxy]ethyl]-
 (9CI) (CA INDEX NAME)




RN 436856-44-9 CAPLUS
 CN Benzamide, N-[2-[2-(4-amino-1H-imidazo[4,5-c]quinolin-1-yl)ethoxy]ethyl]-
 (9CI) (CA INDEX NAME)




RN 436856-46-1 CAPLUS
 CN Cyclohexanecarboxamide, N-[2-[2-(4-amino-1H-imidazo[4,5-c]quinolin-1-yl)ethoxy]ethyl]- (9CI) (CA INDEX NAME)







RN 436856-48-3 CAPLUS
 CN Benzeneacetamide, N-[2-[2-(4-amino-1H-imidazo[4,5-c]quinolin-1-yl)ethoxy]ethyl]- (9CI) (CA INDEX NAME)



RN 436856-50-7 CAPLUS
 CN 2-Thiopheneacetamide, N-[2-[2-(4-amino-1H-imidazo[4,5-c]quinolin-1-yl)ethoxy]ethyl]- (9CI) (CA INDEX NAME)




10681711


RN 436856-52-9 CAPLUS

CN Benzanide, N-[2-[2-(4-amino-1H-imidazo[4,5-c]quinolin-1-yl)ethoxy]ethyl]-4-cyano- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A





RN 436856-54-1 CAPLUS

CN Benzenepropanamide, N-[2-[2-(4-amino-1H-imidazo[4,5-c]quinolin-1-yl)ethoxy]ethyl]- (9CI) (CA INDEX NAME)




RN 436856-56-3 CAPLUS


CN Benzanide, N-[2-[2-(4-amino-1H-imidazo[4,5-c]quinolin-1-yl)ethoxy]ethyl]-3-methoxy- (9CI) (CA INDEX NAME)





RN 436856-58-5 CAPLUS

CN Benzamide, N-[2-[2-(4-amino-1H-imidazo[4,5-c]quinolin-1-yl)ethoxy]ethyl]-4-methoxy- (9CI) (CA INDEX NAME)






RN 436856-60-9 CAPLUS
 CN 3-Pyridinecarboxamide, N-[2-[2-(4-amino-1H-imidazo[4,5-c]quinolin-1-yl)ethoxy]ethyl]-6-chloro- (9CI) (CA INDEX NAME)




RN 436856-62-1 CAPLUS
 CN Acetamide, N-[2-[2-(4-amino-1H-imidazo[4,5-c]quinolin-1-yl)ethoxy]ethyl]-2-(phenylmethoxy)- (9CI) (CA INDEX NAME)



RN 436856-64-3 CAPLUS

10681711


CN 2-Naphthalenecarboxamide, N-[2-[2-(4-amino-1H-imidazo[4,5-c]quinolin-1-yl)ethoxy]ethyl]- (9CI) (CA INDEX NAME)




RN 436856-66-5 CAPLUS

CN Benzamide, N-[2-[2-(4-amino-1H-imidazo[4,5-c]quinolin-1-yl)ethoxy]ethyl]-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A




RN 436856-68-7 CAPLUS

CN Benzamide, N-[2-[2-(4-amino-1H-imidazo[4,5-c]quinolin-1-yl)ethoxy]ethyl]-4-


10681711

(trifluoromethyl)- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 436856-70-1 CAPLUS

CN Benzamide, N-[2-[2-(4-amino-1H-imidazo[4,5-c]quinolin-1-yl)ethoxy]ethyl]-4-(trifluoromethoxy)- (9CI) (CA INDEX NAME)


PAGE 1-A






RN 608512-33-0 CAPLUS

CN Benzamide, N-[2-[2-(4-amino-2-methyl-1H-imidazo[4,5-c]quinolin-1-yl)ethoxy]ethyl]- (9CI) (CA INDEX NAME)




RN 608512-34-1 CAPLUS

CN Benzamide, N-[2-[2-(4-amino-2-ethyl-1H-imidazo[4,5-c]quinolin-1-yl)ethoxy]ethyl]- (9CI) (CA INDEX NAME)





RN 608512-35-2 CAPLUS

CN Benzamide, N-[2-[2-(4-amino-2-(ethoxymethyl)-1H-imidazo[4,5-c]quinolin-1-yl)ethoxy]ethyl]- (9CI) (CA INDEX NAME)



RN 608512-36-3 CAPLUS

CN Cyclohexanecarboxamide, N-[2-[2-(4-amino-2-(2-methoxyethyl)-1H-imidazo[4,5-c]quinolin-1-yl)ethoxy]ethyl]-N-methyl- (9CI) (CA INDEX NAME)




IT 436856-84-7P 436856-92-7P 436856-98-3P
 436857-12-4P 557787-40-3P 557787-44-7P
 557787-47-0P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
 (Reactant or reagent)
 (preparation of amido ether substituted imidazoquinolines as immune response
 modifiers)

RN 436856-84-7 CAPLUS


CN Carbamic acid, [2-[2-(4-amino-2-butyl-1H-imidazo[4,5-c]quinolin-1-yl)ethoxy]ethyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 436856-92-7 CAPLUS


CN Carbamic acid, [2-[2-(4-amino-1H-imidazo[4,5-c]quinolin-1-yl)ethoxy]ethyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

10681711




RN 436856-98-3 CAPLUS

CN Carbamic acid, [2-[2-[4-amino-2-(2-methoxyethyl)-1H-imidazo[4,5-c]quinolin-1-yl]ethoxy]ethyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 436857-12-4 CAPLUS

CN Carbamic acid, [2-[2-[4-amino-2-(2-methoxyethyl)-1H-imidazo[4,5-c]quinolin-1-yl]ethoxy]ethyl]methyl-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 557787-40-3 CAPLUS


CN Carbamic acid, [2-[2-(4-amino-2-methyl-1H-imidazo[4,5-c]quinolin-1-yl)ethoxy]ethyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 557787-44-7 CAPLUS

CN Carbamic acid, [2-[2-(4-amino-2-ethyl-1H-imidazo[4,5-c]quinolin-1-yl)ethoxy]ethyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

10681711




RN 557787-47-0 CAPLUS
 CN Carbamic acid, [2-[2-[4-amino-2-(ethoxymethyl)-1H-imidazo[4,5-c]quinolin-1-yl]ethoxy]ethyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



L4 ANSWER 5 OF 10 CAPLUS COPYRIGHT 2004 ACS on STN
 AN 2003:570648 CAPLUS
 DN 139:133563
 TI Preparation of sulfonamidoalkoxyalkylimidazoquinolines as immune response modulators.
 IN Crooks, Stephen L.; Griesgraber, George W.; Heppner, Philip D.; Merrill, Bryon A.; Roberts, Ralph R.; Wei, Ai-Ping
 PA 3M Innovative Properties Co., USA
 SO U.S. Pat. Appl. Publ., 46 pp., Cont.-in-part of U.S. Ser. No. 12,599.
 CODEN: USXXCO
 DT Patent
 LA English
 FAN.CNT 11

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 2003139441	A1	20030724	US 2002-165443	20020607
	US 6677347	B2	20040113		
	US 2002193396	A1	20021219	US 2001-12599	20011201
	US 6683088	B2	20040127		
	US 2004072858	A1	20040415	US 2003-675833	20030930
PRAI	US 2000-254218P	P	20001208		
	US 2001-12599	A2	20011201		
	US 2001-11921	A1	20011206		
OS	MARPAT 139:133563				
GI					




I


AB Title compds. [I; X = CHR5, CHR5, CHR5, R1 = R4NR3SO2R6A, R4NR3SOR7, R4NR3SO2NR5R6A, R4NR3SO2NH2; A = alkyl, alkenyl, aryl, heteroaryl, heterocyclyl; R2 = H, (substituted) alkyl, alkenyl, aryl, heteroaryl, heterocyclyl, alkyl-Y-alkyl, alkyl-Y-alkenyl, alkyl-Y-aryl; Y = O, S(O)O-2; R3 = H, alkyl, arylalkyl; R4 = alkyl, alkenyl, which may be interrupted by ≥1 O; R3R4 form a ring; R5 = H, alkyl, alkenyl; R6 = bond, alkyl, alkenyl, which may be interrupted by ≥1 O; R7 = alkyl; R3R7 form a ring; n = 0-4; R = alkyl, alkoxy, OH, halo, CF3], were prepared

Thus, tert-Bu 2-[2-[(3-aminoquinolin-4-yl)amino]ethoxy]ethylcarbamate (preparation given) in CH₂Cl₂ was cooled to 0° and treated with Et₃N and methoxypropionyl chloride; The reaction was then warmed to room temperature and stirring was continued for 1 h to give tert-Bu 2-[2-[2-(2-methoxyethyl)-1H-imidazo[4,5-c]quinolin-1-yl]ethoxy]ethylcarbamate: This was converted to N-[2-[2-[4-amino-2-(2-methoxyethyl)-1H-imidazo[4,5-c]quinolin-1-yl]ethoxy]ethyl]methanesulfonamide in several steps. I showed interferon induction in human cells with lowest effective concns. of 0.0001-1 μM.


- IT **436856-84-7P 436856-92-7P**, tert-Butyl
[2-[2-(4-amino-1H-imidazo[4,5-c]quinolin-1-yl)ethoxy]ethyl]carbamate
436856-98-3P 436857-12-4P 557787-40-3P,
tert-Butyl [2-[2-(4-amino-2-methyl-1H-imidazo[4,5-c]quinolin-1-yl)ethoxy]ethyl]carbamate **557787-44-7P**, tert-Butyl
[2-[2-(4-amino-2-ethyl-1H-imidazo[4,5-c]quinolin-1-yl)ethoxy]ethyl]carbamate **557787-47-0P**, tert-Butyl
[2-[2-(4-amino-2-(ethoxymethyl)-1H-imidazo[4,5-c]quinolin-1-yl)ethoxy]ethyl]carbamate
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
(Reactant or reagent)
(preparation of sulfonamidoalkoxyalkylimidazoquinolines as immune response modulators)
RN 436856-84-7 CAPLUS
CN Carbamic acid, [2-[2-(4-amino-2-butyl-1H-imidazo[4,5-c]quinolin-1-yl)ethoxy]ethyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



- RN 436856-92-7 CAPLUS
CN Carbamic acid, [2-[2-(4-amino-1H-imidazo[4,5-c]quinolin-1-yl)ethoxy]ethyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




- RN 436856-98-3 CAPLUS
CN Carbamic acid, [2-[2-[4-amino-2-(2-methoxyethyl)-1H-imidazo[4,5-c]quinolin-1-yl]ethoxy]ethyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




- RN 436857-12-4 CAPLUS
CN Carbamic acid, [2-[2-[4-amino-2-(2-methoxyethyl)-1H-imidazo[4,5-c]quinolin-1-yl]ethoxy]ethyl]methyl-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

10681711




RN 557787-40-3 CAPLUS

CN Carbamic acid, [2-[2-(4-amino-2-methyl-1H-imidazo[4,5-c]quinolin-1-yl)ethoxy]ethyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 557787-44-7 CAPLUS

CN Carbamic acid, [2-[2-(4-amino-2-ethyl-1H-imidazo[4,5-c]quinolin-1-yl)ethoxy]ethyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 557787-47-0 CAPLUS

CN Carbamic acid, [2-[2-(4-amino-2-(ethoxymethyl)-1H-imidazo[4,5-c]quinolin-1-yl)ethoxy]ethyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



L4 ANSWER 6 OF 10 CAPLUS COPYRIGHT 2004 ACS on STN

AN 2003:532388 CAPLUS

DN 139:101126

TI Preparation of 4-amino-1-(ureidoethoxyethyl)imidazoquinolines as inducers of cytokine biosynthesis for treatment of viral and neoplastic disease.

IN Crooks, Stephen L.; Griesgraber, George W.; Heppner, Philip D.; Merrill, Bryon A.

PA 3M Innovative Properties Co., USA

SO U.S. Pat. Appl. Publ., 43 pp., Cont.-in-part of U.S. Ser. No. 13,060.


CODEN: USXXCO

DT Patent

10681711

LA English
FAN.CNT 11

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 2003130518	A1	20030710	US 2002-164816	20020607
	US 6660735	B2	20031209		
	US 2003158192	A1	20030821	US 2001-13060	20011206
	US 6656938	B2	20031202		
	US 2004072858	A1	20040415	US 2003-675833	20030930
	US 2004072859	A1	20040415	US 2003-681814	20031007
	US 2004077678	A1	20040422	US 2003-680989	20031007
PRAI	US 2000-254218P	P	20001208		
	US 2001-13060	A2	20011206		
	US 2001-11921	A1	20011206		
	US 2002-164816	A1	20020607		
OS	MARPAT 139:101126				
GI					



AB Title compds. [I; X = CHR5, CHR5A; A = alkylene, alkenylene; R1 = R4NR8CR3NR5ZR6A1, R4NR8CR3NR5R7, R4NR8CR3NR9ZR6A1; A1 = alkyl, alkenyl, aryl, heteroaryl, heterocyclyl; R2 = H, alkyl, alkenyl, aryl, heteroaryl, heterocyclyl, alkyl-Y-alkyl, alkyl-Y-alkenyl, alkyl-Y-aryl, alkyl, alkenyl substituted by ≥ 1 of: OH, halo, N(R5)2, CON(R5)2, CO-C1-10 alkyl, CO2-C1-10 alkyl, N3, aryl, heteroaryl, heterocyclyl, CO-aryl, CO-heteroaryl; R3 = O, S; R4 = alkyl, alkenyl, which may be interrupted by ≥ 1 O; R5 = H, C1-10 alkyl; R6 = bond, alkyl, alkenyl, which may be interrupted by ≥ 1 O; R7 = H, C1-10 alkyl which may be interrupted by a heteroatom; R7R5 = atoms to form a ring; R8 = H, C1-10 alkyl, arylalkyl; R4R8 = atoms to form a ring; R9 = C1-10 alkyl which can join together with R8 to form a ring; Y = O, S, SO, SO2; Z = bond, CO, SO2; n = 0-4; R = C1-10 alkyl, C1-10 alkoxy, OH, halo, CF3], were prepared. Thus, title compound I (R1 = morpholinocarbonylaminoethyl; X = CH2CH2; R2 = Bu; R = null) (general preparation given) induced interferon and tumor necrosis factor in human cells at lowest effective concns. of 0.0001 μ M and 0.1 μ M, resp.

IT **437383-04-5P**, N-[2-[2-[4-Amino-2-(2-methoxyethyl)-1H-imidazo[4,5-c]quinolin-1-yl]ethoxy]ethyl]-N'-phenylurea **437383-05-6P**, N-[2-[2-[4-Amino-2-(2-methoxyethyl)-6,7,8,9-tetrahydro-1H-imidazo[4,5-c]quinolin-1-yl]ethoxy]ethyl]-N'-phenylurea **437383-06-7P**, N-[2-[2-[4-Amino-2-(2-methoxyethyl)-1H-imidazo[4,5-c]quinolin-1-yl]ethoxy]ethyl]-N-methyl-N'-phenylurea **437383-07-8P**, N-[2-[2-[4-Amino-2-(2-methoxyethyl)-6,7,8,9-tetrahydro-1H-imidazo[4,5-c]quinolin-1-yl]ethoxy]ethyl]-N-methyl-N'-phenylurea **437383-08-9P**, N-[2-[2-[4-Amino-2-(2-methoxyethyl)-1H-imidazo[4,5-c]quinolin-1-yl]ethoxy]ethyl]morpholine-4-carboxamide **437383-09-0P**, N-[2-[2-[4-Amino-2-(2-methoxyethyl)-1H-imidazo[4,5-c]quinolin-1-yl]ethoxy]ethyl]-N-methylmorpholine-4-carboxamide **437383-10-3P**
437383-11-4P 437383-12-5P 437383-13-6P
437383-14-7P 437383-15-8P 437383-16-9P
437383-17-0P 437383-18-1P 437383-19-2P
437383-20-5P 437383-21-6P 437383-22-7P
437383-23-8P 437383-24-9P 437383-40-9P
437383-41-0P 437383-42-1P 437383-43-2P
437383-44-3P 437383-45-4P 437383-46-5P
437383-47-6P 557787-30-1P 557787-31-2P
557787-32-3P 557787-33-4P 557787-34-5P
557787-35-6P 557787-36-7P 557787-37-8P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)


(preparation of aminoureidoethoxyethylimidazoquinolines as inducers of cytokine biosynthesis for treatment of viral and neoplastic disease)

RN 437383-04-5 CAPLUS

CN Urea, N-[2-[2-[4-amino-2-(2-methoxyethyl)-1H-imidazo[4,5-c]quinolin-1-


10681711

yl]ethoxy]ethyl]-N'-phenyl- (9CI) (CA INDEX NAME)




RN 437383-05-6 CAPLUS

CN Urea, N-[2-[2-[4-amino-6,7,8,9-tetrahydro-2-(2-methoxyethyl)-1H-imidazo[4,5-c]quinolin-1-yl]ethoxy]ethyl]-N'-phenyl- (9CI) (CA INDEX NAME)




RN 437383-06-7 CAPLUS

CN Urea, N-[2-[2-[4-amino-2-(2-methoxyethyl)-1H-imidazo[4,5-c]quinolin-1-yl]ethoxy]ethyl]-N-methyl-N'-phenyl- (9CI) (CA INDEX NAME)





RN 437383-07-8 CAPLUS

CN Urea, N-[2-[2-[4-amino-6,7,8,9-tetrahydro-2-(2-methoxyethyl)-1H-imidazo[4,5-c]quinolin-1-yl]ethoxy]ethyl]-N-methyl-N'-phenyl- (9CI) (CA INDEX NAME)





RN 437383-08-9 CAPLUS

CN 4-Morpholinecarboxamide, N-[2-[2-[4-amino-2-(2-methoxyethyl)-1H-imidazo[4,5-c]quinolin-1-yl]ethoxy]ethyl]- (9CI) (CA INDEX NAME)




RN 437383-09-0 CAPLUS
 CN 4-Morpholinecarboxamide, N-[2-[2-[4-amino-2-(2-methoxyethyl)-1H-imidazo[4,5-c]quinolin-1-yl]ethoxy]ethyl]-N-methyl- (9CI) (CA INDEX NAME)






RN 437383-10-3 CAPLUS

CN Urea, N-[2-[2-(4-amino-2-butyl-1H-imidazo[4,5-c]quinolin-1-yl)ethoxy]ethyl]-N'-(1-methylethyl)- (9CI) (CA INDEX NAME)




RN 437383-11-4 CAPLUS

CN Urea, N-[2-[2-(4-amino-2-butyl-1H-imidazo[4,5-c]quinolin-1-yl)ethoxy]ethyl]-N'-(1,1-dimethylethyl)- (9CI) (CA INDEX NAME)



RN 437383-12-5 CAPLUS


CN Urea, N-[2-[2-(4-amino-2-butyl-1H-imidazo[4,5-c]quinolin-1-yl)ethoxy]ethyl]-N'-butyl- (9CI) (CA INDEX NAME)



RN 437383-13-6 CAPLUS


CN Urea, N-[2-[2-(4-amino-2-butyl-1H-imidazo[4,5-c]quinolin-1-yl)ethoxy]ethyl]-N'-phenyl- (9CI) (CA INDEX NAME)

10681711




RN 437383-14-7 CAPLUS
CN 4-Morpholinecarboxamide, N-[2-[2-(4-amino-2-butyl-1H-imidazo[4,5-c]quinolin-1-yl)ethoxy]ethyl]- (9CI) (CA INDEX NAME)



PAGE 1-A




PAGE 2-A



RN 437383-15-8 CAPLUS
CN Urea, N-[2-[2-(4-amino-2-butyl-1H-imidazo[4,5-c]quinolin-1-yl)ethoxy]ethyl]-N'-cyclohexyl- (9CI) (CA INDEX NAME)




RN 437383-16-9 CAPLUS
 CN Urea, N-[2-[2-(4-amino-2-butyl-1H-imidazo[4,5-c]quinolin-1-yl)ethoxy]ethyl]-N'-(3-cyanophenyl)- (9CI) (CA INDEX NAME)




10681711

PAGE 2-A




RN 437383-17-0 CAPLUS
CN Urea, N-[2-[2-(4-amino-2-butyl-1H-imidazo[4,5-c]quinolin-1-yl)ethoxy]ethyl]-N'-(3-methoxyphenyl)- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A



RN 437383-18-1 CAPLUS
CN Urea, N-[2-[2-(4-amino-2-butyl-1H-imidazo[4,5-c]quinolin-1-yl)ethoxy]ethyl]-N'-[(1R,2S)-2-phenylcyclopropyl]-, rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.

10681711




RN 437383-19-2 CAPLUS
CN Urea, N-[2-[2-(4-amino-2-butyl-1H-imidazo[4,5-c]quinolin-1-yl)ethoxy]ethyl]-N'-(4-(dimethylamino)phenyl)- (9CI) (CA INDEX NAME)



PAGE 1-A




PAGE 2-A




RN 437383-20-5 CAPLUS
CN Urea, N-[2-[2-(4-amino-2-butyl-1H-imidazo[4,5-c]quinolin-1-yl)ethoxy]ethyl]-N'-(3-(methylthio)phenyl)- (9CI) (CA INDEX NAME)




RN 437383-21-6 CAPLUS
 CN Urea, N-[2-[2-(4-amino-2-butyl-1H-imidazo[4,5-c]quinolin-1-yl)ethoxy]ethyl]-N'-(2,4-dimethoxyphenyl)- (9CI) (CA INDEX NAME)







RN 437383-22-7 CAPLUS

CN Benzenesulfonamide, N-[[[2-[2-(4-amino-2-butyl-1H-imidazo[4,5-c]quinolin-1-yl)ethoxy]ethyl]amino]carbonyl]- (9CI) (CA INDEX NAME)



RN 437383-23-8 CAPLUS

CN Benzenesulfonamide, N-[[[2-[2-(4-amino-2-butyl-1H-imidazo[4,5-c]quinolin-1-yl)ethoxy]ethyl]amino]carbonyl]-4-methyl- (9CI) (CA INDEX NAME)




RN 437383-24-9 CAPLUS


10681711

CN Benzenesulfonamide, N-[[[2-[2-(4-amino-2-butyl-1H-imidazo[4,5-c]quinolin-1-yl)ethoxy]ethyl]amino]carbonyl]-4-chloro- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A



RN 437383-40-9 CAPLUS


CN Urea, N-[2-[2-(4-amino-1H-imidazo[4,5-c]quinolin-1-yl)ethoxy]ethyl]-N'-(1,1-dimethylethyl)- (9CI) (CA INDEX NAME)



RN 437383-41-0 CAPLUS


CN Urea, N-[2-[2-(4-amino-1H-imidazo[4,5-c]quinolin-1-yl)ethoxy]ethyl]-N'-phenyl- (9CI) (CA INDEX NAME)

10681711




RN 437383-42-1 CAPLUS
CN Urea, N-[2-[2-(4-amino-1H-imidazo[4,5-c]quinolin-1-yl)ethoxy]ethyl]-N'-cyclohexyl- (9CI) (CA INDEX NAME)



PAGE 1-A




PAGE 2-A




RN 437383-43-2 CAPLUS
CN Urea, N-[2-[2-(4-amino-1H-imidazo[4,5-c]quinolin-1-yl)ethoxy]ethyl]-N'-(3-cyanophenyl)- (9CI) (CA INDEX NAME)



RN 437383-44-3 CAPLUS
 CN Urea, N-[2-[2-(4-amino-1H-imidazo[4,5-c]quinolin-1-yl)ethoxy]ethyl]-N'-(3-methoxyphenyl)- (9CI) (CA INDEX NAME)






RN 437383-45-4 CAPLUS


CN Urea, N-[2-[2-(4-amino-1H-imidazo[4,5-c]quinolin-1-yl)ethoxy]ethyl]-N'-[(1R,2S)-2-phenylcyclopropyl]-, rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.




RN 437383-46-5 CAPLUS

CN Urea, N-[2-[2-(4-amino-1H-imidazo[4,5-c]quinolin-1-yl)ethoxy]ethyl]-N'-(2,4-dimethoxyphenyl)- (9CI) (CA INDEX NAME)







RN 437383-47-6 CAPLUS
 CN Benzenesulfonamide, N-[[[2-[2-(4-amino-1H-imidazo[4,5-c]quinolin-1-yl)ethoxy]ethyl]amino]carbonyl]- (9CI) (CA INDEX NAME)




RN 557787-30-1 CAPLUS
 CN Urea, N-[2-[2-(4-amino-2-methyl-1H-imidazo[4,5-c]quinolin-1-yl)ethoxy]ethyl]-N'-cyclohexyl- (9CI) (CA INDEX NAME)



RN 557787-31-2 CAPLUS

10681711


CN Urea, N-[2-[2-(4-amino-2-ethyl-1H-imidazo[4,5-c]quinolin-1-yl)ethoxy]ethyl]-N'-phenyl- (9CI) (CA INDEX NAME)




RN 557787-32-3 CAPLUS

CN Urea, N-[2-[2-(4-amino-2-ethyl-1H-imidazo[4,5-c]quinolin-1-yl)ethoxy]ethyl]-N'-cyclohexyl- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A



RN 557787-33-4 CAPLUS


CN Urea, N-[2-[2-(4-amino-2-methyl-1H-imidazo[4,5-c]quinolin-1-yl)ethoxy]ethyl]-N'-phenyl- (9CI) (CA INDEX NAME)

10681711




RN 557787-34-5 CAPLUS
CN Urea, N-[2-[2-(4-amino-2-ethyl-1H-imidazo[4,5-c]quinolin-1-yl)ethoxy]ethyl]-N'-4-morpholinyl- (9CI) (CA INDEX NAME)


PAGE 1-A



PAGE 2-A



RN 557787-35-6 CAPLUS
CN Urea, N-[2-[2-[4-amino-2-(ethoxymethyl)-1H-imidazo[4,5-c]quinolin-1-yl)ethoxy]ethyl]-N'-phenyl- (9CI) (CA INDEX NAME)




RN 557787-36-7 CAPLUS


10681711

CN Urea, N-[2-[2-[4-amino-2-(ethoxymethyl)-1H-imidazo[4,5-c]quinolin-1-yl]ethoxy]ethyl]-N'-cyclohexyl- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 557787-37-8 CAPLUS

CN 4-Morpholinecarboxamide, N-[2-[2-[4-amino-2-(ethoxymethyl)-1H-imidazo[4,5-c]quinolin-1-yl]ethoxy]ethyl]- (9CI) (CA INDEX NAME)

PAGE 1-A






IT 436856-84-7P 436856-92-7P 436856-98-3P
436857-12-4P 557787-40-3P 557787-44-7P
557787-47-0P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation of aminoureidoethoxyethylimidazoquinolines as inducers of cytokine biosynthesis for treatment of viral and neoplastic disease)


RN 436856-84-7 CAPLUS

CN Carbamic acid, [2-[2-(4-amino-2-butyl-1H-imidazo[4,5-c]quinolin-1-yl)ethoxy]ethyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 436856-92-7 CAPLUS

CN Carbamic acid, [2-[2-(4-amino-1H-imidazo[4,5-c]quinolin-1-yl)ethoxy]ethyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 436856-98-3 CAPLUS

CN Carbamic acid, [2-[2-[4-amino-2-(2-methoxyethyl)-1H-imidazo[4,5-c]quinolin-1-yl]ethoxy]ethyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 436857-12-4 CAPLUS

CN Carbamic acid, [2-[2-[4-amino-2-(2-methoxyethyl)-1H-imidazo[4,5-c]quinolin-1-yl]ethoxy]ethyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)


10681711

1-yl]ethoxy]ethyl]methyl-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 557787-40-3 CAPLUS

CN Carbamic acid, [2-[2-(4-amino-2-methyl-1H-imidazo[4,5-c]quinolin-1-yl)ethoxy]ethyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 557787-44-7 CAPLUS

CN Carbamic acid, [2-[2-(4-amino-2-ethyl-1H-imidazo[4,5-c]quinolin-1-yl)ethoxy]ethyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 557787-47-0 CAPLUS

CN Carbamic acid, [2-[2-(4-amino-2-(ethoxymethyl)-1H-imidazo[4,5-c]quinolin-1-yl)ethoxy]ethyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



L4 ANSWER 7 OF 10 CAPLUS COPYRIGHT 2004 ACS on STN

AN 2002:449682 CAPLUS

DN 137:33298

TI Preparation of urea substituted imidazoquinoline ethers as immune response modifiers

IN Crooks, Stephen L.; Griesgraber, George W.; Heppner, Philip D.; Merrill, Bryon A.


PA 3M Innovative Properties Company, USA

SO PCT Int. Appl., 71 pp.

10681711

CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 11

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2002046191	A2	20020613	WO 2001-US46696	20011206
	WO 2002046191	A3	20030313		
	W:		AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ		
	RW:		GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG		
	AU 2002032497	A5	20020618	AU 2002-32497	20011206
	US 2003065005	A1	20030403	US 2001-11921	20011206
	US 6664260	B2	20031216		
	EP 1343784	A2	20030917	EP 2001-992018	20011206
	R:		AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR		
	EE 200300272	A	20031015	EE 2003-272	20011206
	NO 2003002449	A	20030528	NO 2003-2449	20030528
	US 2004072858	A1	20040415	US 2003-675833	20030930
PRAI	US 2000-254218P	P	20001208		
	US 2001-11921	A1	20011206		
	WO 2001-US46696	W	20011206		
OS	MARPAT 137:33298				
GI					



AB The title compds. [I; X = (CH₂)₂, CH₂CH₂, etc.; R₁ = R₄NR₈CR₃NR₅ZR₆alkyl, R₄NR₈CR₃NR₅ZR₆aryl, etc.; R₂ = H, alkyl, aryl, etc.; R₃ = O, S; R₄ = alkylene or alkenylene which may be interrupted by one or more O atoms; R₅ = H, alkyl; R₆ = a bond, alkylene or alkenylene which may be interrupted by one or more O atoms; R₈ = H, alkyl, aralkyl; or R₄ and R₈ can join together to form a ring; Z = a bond, CO, SO₂; n = 0-4; R = alkyl, alkoxy, OH, etc.] that contain ether and urea functionality at the 1-position, and are useful as immune response modifiers, were prepared E.g., a multi-step synthesis of the urea I [X = (CH₂)₂; R₁ = (CH₂)₂NMeCONHPh; R₂ = (CH₂)₂OMe; n = 0] which showed the lowest concentration of 0.01 μM and 0.37 μM to induce interferon α and TNFα, resp., was prepared The compds. I can induce the biosynthesis of various cytokines and are useful in the treatment of a variety of conditions including viral diseases and neoplastic diseases.

IT 437383-04-5P 437383-05-6P 437383-06-7P
437383-07-8P 437383-08-9P 437383-09-0P
437383-10-3P 437383-11-4P 437383-12-5P
437383-13-6P 437383-14-7P 437383-15-8P
437383-16-9P 437383-17-0P 437383-18-1P
437383-19-2P 437383-20-5P 437383-21-6P
437383-22-7P 437383-23-8P 437383-24-9P
437383-40-9P 437383-41-0P 437383-42-1P
437383-43-2P 437383-44-3P 437383-45-4P
437383-46-5P 437383-47-6P


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

10681711

(preparation of urea substituted imidazoquinoline ethers as immune response modifiers)


RN 437383-04-5 CAPLUS

CN Urea, N-[2-[2-[4-amino-2-(2-methoxyethyl)-1H-imidazo[4,5-c]quinolin-1-yl]ethoxy]ethyl]-N'-phenyl- (9CI) (CA INDEX NAME)




RN 437383-05-6 CAPLUS

CN Urea, N-[2-[2-[4-amino-6,7,8,9-tetrahydro-2-(2-methoxyethyl)-1H-imidazo[4,5-c]quinolin-1-yl]ethoxy]ethyl]-N'-phenyl- (9CI) (CA INDEX NAME)




RN 437383-06-7 CAPLUS

CN Urea, N-[2-[2-[4-amino-2-(2-methoxyethyl)-1H-imidazo[4,5-c]quinolin-1-yl]ethoxy]ethyl]-N-methyl-N'-phenyl- (9CI) (CA INDEX NAME)





RN 437383-07-8 CAPLUS

CN Urea, N-[2-[2-[4-amino-6,7,8,9-tetrahydro-2-(2-methoxyethyl)-1H-imidazo[4,5-c]quinolin-1-yl]ethoxy]ethyl]-N-methyl-N'-phenyl- (9CI) (CA INDEX NAME)





RN 437383-08-9 CAPLUS

CN 4-Morpholinecarboxamide, N-[2-[2-[4-amino-2-(2-methoxyethyl)-1H-imidazo[4,5-c]quinolin-1-yl]ethoxy]ethyl]- (9CI) (CA INDEX NAME)




RN 437383-09-0 CAPLUS
 CN 4-Morpholinecarboxamide, N-[2-[2-[4-amino-2-(2-methoxyethyl)-1H-imidazo[4,5-c]quinolin-1-yl]ethoxy]ethyl]-N-methyl- (9CI) (CA INDEX NAME)






RN 437383-10-3 CAPLUS

CN Urea, N-[2-[2-(4-amino-2-butyl-1H-imidazo[4,5-c]quinolin-1-yl)ethoxy]ethyl]-N'-(1-methylethyl)- (9CI) (CA INDEX NAME)




RN 437383-11-4 CAPLUS

CN Urea, N-[2-[2-(4-amino-2-butyl-1H-imidazo[4,5-c]quinolin-1-yl)ethoxy]ethyl]-N'-(1,1-dimethylethyl)- (9CI) (CA INDEX NAME)



RN 437383-12-5 CAPLUS


CN Urea, N-[2-[2-(4-amino-2-butyl-1H-imidazo[4,5-c]quinolin-1-yl)ethoxy]ethyl]-N'-butyl- (9CI) (CA INDEX NAME)



RN 437383-13-6 CAPLUS


CN Urea, N-[2-[2-(4-amino-2-butyl-1H-imidazo[4,5-c]quinolin-1-yl)ethoxy]ethyl]-N'-phenyl- (9CI) (CA INDEX NAME)

10681711




RN 437383-14-7 CAPLUS
CN 4-Morpholinecarboxamide, N-[2-[2-(4-amino-2-butyl-1H-imidazo[4,5-c]quinolin-1-yl)ethoxy]ethyl]- (9CI) (CA INDEX NAME)



PAGE 1-A




PAGE 2-A




RN 437383-15-8 CAPLUS
CN Urea, N-[2-[2-(4-amino-2-butyl-1H-imidazo[4,5-c]quinolin-1-yl)ethoxy]ethyl]-N'-cyclohexyl- (9CI) (CA INDEX NAME)





RN 437383-16-9 CAPLUS
 CN Urea, N-[2-[2-(4-amino-2-butyl-1H-imidazo[4,5-c]quinolin-1-yl)ethoxy]ethyl]-N'-(3-cyanophenyl)- (9CI) (CA INDEX NAME)






RN 437383-17-0 CAPLUS
 CN Urea, N-[2-[2-(4-amino-2-butyl-1H-imidazo[4,5-c]quinolin-1-yl)ethoxy]ethyl]-N'-(3-methoxyphenyl)- (9CI) (CA INDEX NAME)



RN 437383-18-1 CAPLUS
 CN Urea, N-[2-[2-(4-amino-2-butyl-1H-imidazo[4,5-c]quinolin-1-yl)ethoxy]ethyl]-N'-[(1R,2S)-2-phenylcyclopropyl]-, rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.

10681711




RN 437383-19-2 CAPLUS
CN Urea, N-[2-[2-(4-amino-2-butyl-1H-imidazo[4,5-c]quinolin-1-yl)ethoxy]ethyl]-N'-(4-(dimethylamino)phenyl)- (9CI) (CA INDEX NAME)



PAGE 1-A




PAGE 2-A




RN 437383-20-5 CAPLUS
CN Urea, N-[2-[2-(4-amino-2-butyl-1H-imidazo[4,5-c]quinolin-1-yl)ethoxy]ethyl]-N'-(3-(methylthio)phenyl)- (9CI) (CA INDEX NAME)




RN 437383-21-6 CAPLUS
 CN Urea, N-[2-[2-(4-amino-2-butyl-1H-imidazo[4,5-c]quinolin-1-yl)ethoxy]ethyl]-N'-(2,4-dimethoxyphenyl)- (9CI) (CA INDEX NAME)







RN 437383-22-7 CAPLUS

CN Benzenesulfonamide, N-[[[2-[2-(4-amino-2-butyl-1H-imidazo[4,5-c]quinolin-1-yl)ethoxy]ethyl]amino]carbonyl]- (9CI) (CA INDEX NAME)



RN 437383-23-8 CAPLUS

CN Benzenesulfonamide, N-[[[2-[2-(4-amino-2-butyl-1H-imidazo[4,5-c]quinolin-1-yl)ethoxy]ethyl]amino]carbonyl]-4-methyl- (9CI) (CA INDEX NAME)




RN 437383-24-9 CAPLUS


10681711

CN Benzenesulfonamide, N-[[[2-[2-(4-amino-2-butyl-1H-imidazo[4,5-c]quinolin-1-yl)ethoxy]ethyl]amino]carbonyl]-4-chloro- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A



RN 437383-40-9 CAPLUS


CN Urea, N-[2-[2-(4-amino-1H-imidazo[4,5-c]quinolin-1-yl)ethoxy]ethyl]-N'-(1,1-dimethylethyl)- (9CI) (CA INDEX NAME)



RN 437383-41-0 CAPLUS


CN Urea, N-[2-[2-(4-amino-1H-imidazo[4,5-c]quinolin-1-yl)ethoxy]ethyl]-N'-phenyl- (9CI) (CA INDEX NAME)

10681711




RN 437383-42-1 CAPLUS
CN Urea, N-[2-[2-(4-amino-1H-imidazo[4,5-c]quinolin-1-yl)ethoxy]ethyl]-N'-cyclohexyl- (9CI) (CA INDEX NAME)



PAGE 1-A



PAGE 2-A





RN 437383-43-2 CAPLUS
CN Urea, N-[2-[2-(4-amino-1H-imidazo[4,5-c]quinolin-1-yl)ethoxy]ethyl]-N'-(3-cyanophenyl)- (9CI) (CA INDEX NAME)



RN 437383-44-3 CAPLUS

CN Urea, N-[2-[2-(4-amino-1H-imidazo[4,5-c]quinolin-1-yl)ethoxy]ethyl]-N'-(3-methoxyphenyl)- (9CI) (CA INDEX NAME)






RN 437383-45-4 CAPLUS


CN Urea, N-[2-[2-(4-amino-1H-imidazo[4,5-c]quinolin-1-yl)ethoxy]ethyl]-N'-[(1R,2S)-2-phenylcyclopropyl]-, rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 437383-46-5 CAPLUS


CN Urea, N-[2-[2-(4-amino-1H-imidazo[4,5-c]quinolin-1-yl)ethoxy]ethyl]-N'-(2,4-dimethoxyphenyl)- (9CI) (CA INDEX NAME)





RN 437383-47-6 CAPLUS

CN Benzenesulfonamide, N-[[[2-[2-(4-amino-1H-imidazo[4,5-c]quinolin-1-yl)ethoxy]ethyl]amino]carbonyl]- (9CI) (CA INDEX NAME)




IT **436856-84-7P 436856-92-7P 436856-98-3P**
436857-12-4P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (preparation of urea substituted imidazoquinoline ethers as immune response modifiers)


RN 436856-84-7 CAPLUS

CN Carbamic acid, [2-[2-(4-amino-2-butyl-1H-imidazo[4,5-c]quinolin-1-yl)ethoxy]ethyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 436856-92-7 CAPLUS


CN Carbamic acid, [2-[2-(4-amino-1H-imidazo[4,5-c]quinolin-1-yl)ethoxy]ethyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 436856-98-3 CAPLUS

CN Carbamic acid, [2-[2-(4-amino-2-(2-methoxyethyl)-1H-imidazo[4,5-c]quinolin-1-yl)ethoxy]ethyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

10681711




RN 436857-12-4 CAPLUS
 CN Carbamic acid, [2-[2-[4-amino-2-(2-methoxyethyl)-1H-imidazo[4,5-c]quinolin-1-yl]ethoxy]ethyl)methyl-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



L4 ANSWER 8 OF 10 CAPLUS COPYRIGHT 2004 ACS on STN
 AN 2002:449681 CAPLUS
 DN 137:33297
 TI Preparation of sulfonamido ether substituted imidazoquinolines as immune response modifiers
 IN Crooks, Stephen L.; Greisgraber, George W.; Heppner, Philip D.; Merrill, Bryon A.; Roberts, Ralph R.; Wei, Ai-Ping
 PA 3M Innovative Properties Company, USA
 SO PCT Int. Appl., 74 pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 FAN.CNT 11

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2002046190	A2	20020613	WO 2001-US46582	20011206
	WO 2002046190	A3	20030717		
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ			
	RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
	AU 2002039517	A5	20020618	AU 2002-39517	20011206
	US 2003065005	A1	20030403	US 2001-11921	20011206
	US 6664260	B2	20031216		
	EP 1341790	A2	20030910	EP 2001-987283	20011206
	R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR			
	EE 200300274	A	20031015	EE 2003-274	20011206
	NO 2003002473	A	20030530	NO 2003-2473	20030530
	US 2004072858	A1	20040415	US 2003-675833	20030930
PRAI	US 2000-254218P	P	20001208		
	US 2001-11921	A1	20011206		
	WO 2001-US46582	W	20011206		
OS	MARPAT 137:33297				
GI					




AB The title compds. [I; X = (CH₂)₂, (CH₂)₃, CH₂CH₂, etc.; R₁ = R₄NR₃SO₂R₆alkyl, R₄NR₃SO₂R₆aryl, etc.; R₂ = H, alkyl, alkenyl, etc.; R₃ = H, alkyl, aralkyl; R₄ = alkylene or alkenylene interrupted by one or more O atoms; or R₃R₄ can join together to form a ring; R₆ = a bond, alkylene or alkenylene which may be interrupted by one or more O atoms; n = 0-4; R = alkyl, alkoxy, OH, etc.] that contain substituted amine functionality at the 1-position, and are useful as immune response modifiers, were prepared E.g., a multi-step synthesis of I [X = (CH₂)₂; R₁ = (CH₂)₂NMeSO₂Me; R₂ = (CH₂)₂OMe; n = 0] which showed the lowest concentration of 0.01 μM and 0.12 μM to induce interferon α and TNFα, resp., was given. The compds. I can induce the biosynthesis of various cytokines and are useful in the treatment of a variety of conditions including viral diseases and neoplastic diseases.

IT **436856-84-7P 436856-92-7P 436856-98-3P 436857-12-4P**

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of sulfonamido ether substituted imidazoquinolines as immune response modifiers)


RN 436856-84-7 CAPLUS

CN Carbamic acid, [2-[2-(4-amino-2-butyl-1H-imidazo[4,5-c]quinolin-1-yl)ethoxy]ethyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 436856-92-7 CAPLUS


CN Carbamic acid, [2-[2-(4-amino-1H-imidazo[4,5-c]quinolin-1-yl)ethoxy]ethyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 436856-98-3 CAPLUS

CN Carbamic acid, [2-[2-[4-amino-2-(2-methoxyethyl)-1H-imidazo[4,5-c]quinolin-1-yl]ethoxy]ethyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

10681711




RN 436857-12-4 CAPLUS
CN Carbamic acid, [2-[2-[4-amino-2-(2-methoxyethyl)-1H-imidazo[4,5-c]quinolin-1-yl]ethoxy]ethyl]methyl-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



L4 ANSWER 9 OF 10 CAPLUS COPYRIGHT 2004 ACS on STN
AN 2002:449680 CAPLUS
DN 137:33296
TI Preparation of aryl ether substituted imidazoquinolines as immune response modifiers
IN Charles, Leslie J.; Dellaria, Joseph F.; Heppner, Philip D.; Merrill, Bryon A.; Mickelson, John W.
PA 3M Innovative Properties Company, USA
SO PCT Int. Appl., 184 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 11

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2002046189	A2	20020613	WO 2001-US46581	20011206
	WO 2002046189	A3	20030320		
	W:		AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ		
	RW:		GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG		
	AU 2002039516	A5	20020618	AU 2002-39516	20011206
	US 2003065005	A1	20030403	US 2001-11921	20011206
	US 6664260	B2	20031216		
	EP 1341789	A2	20030910	EP 2001-987282	20011206
	R:		AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR		
	EE 200300270	A	20031015	EE 2003-270	20011206
	NO 2003002452	A	20030716	NO 2003-2452	20030528
	US 2004072858	A1	20040415	US 2003-675833	20030930
PRAI	US 2000-254218P	P	20001208		
	US 2001-11921	A1	20011206		
	WO 2001-US46581	W	20011206		
OS	MARPAT 137:33296				
GI					

10681711



AB The title compds. [I; X = (CH₂)₂, CH₂CH₂, etc.; R₁ = alkenyl, aryl, R₄-aryl; R₂ = H, alkyl, alkenyl, etc.; R₄ = alkyl, alkenyl which may be interrupted by one or more O atoms; R₃ = H, alkyl; n = 0-4; R = alkyl, alkoxy, OH, etc.] that contain ether and aryl or alkenyl functionality at the 1-position, and are useful as immune response modifiers, were prepared E.g., a multi-step synthesis of I [X = (CH₂)₂; R₁ = CH₂C.tplbond.CH; R₂ = H; n = 0] which showed the lowest concentration of 0.12 μM and 1.11 μM to induce interferon α and TNFα, resp., was given. The compds. I can induce the biosynthesis of various cytokines and are useful in the treatment of a variety of conditions including viral diseases and neoplastic diseases.

IT **437601-48-4P**

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of aryl ether substituted imidazoquinolines as immune response modifiers)


RN 437601-48-4 CAPLUS

CN Acetic acid, [2-(4-amino-1H-imidazo[4,5-c]quinolin-1-yl)butoxy]-, methyl ester, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 436855-99-1


CMF C17 H20 N4 O3



CM 2

CRN 76-05-1

CMF C2 H F3 O2



L4 ANSWER 10 OF 10 CAPLUS COPYRIGHT 2004 ACS on STN

AN 2002:449679 CAPLUS

DN 137:33295


TI Preparation of amido ether substituted imidazoquinolines as immune response modifiers

IN Crooks, Stephen L.; Griesgraber, George W.; Heppner, Philip D.; Merrill, Bryon A.

10681711

PA 3M Innovative Properties Company, USA
 SO PCT Int. Appl., 79 pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 FAN.CNT 11

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2002046188	A2	20020613	WO 2001-US46359	20011206
	WO 2002046188	A3	20030313		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	AU 2002032482	A5	20020618	AU 2002-32482	20011206
	US 2003065005	A1	20030403	US 2001-11921	20011206
	US 6664260	B2	20031216		
	EP 1341792	A2	20030910	EP 2001-992005	20011206
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
	EE 200300268	A	20031015	EE 2003-268	20011206
	NO 2003002451	A	20030716	NO 2003-2451	20030528
	US 2004072858	A1	20040415	US 2003-675833	20030930
PRAI	US 2000-254218P	P	20001208		
	US 2001-11921	A1	20011206		
	WO 2001-US46359	W	20011206		
OS	MARPAT 137:33295				
GI					




AB The title compds. [I; X = (CH₂)₂, CH(Et)CH₂, etc.; R₁ = (CH₂)₄CONMePh, (CH₂)₂NHCO(cyclohexyl), (CH₂)₂NHCO(1-naphthyl), etc.; R₂ = H, alkyl, alkenyl, etc.; R = alkyl, alkoxy, OH, halo, CF₃; n = 0-4] and their pharmaceutically acceptable salts that contain ether and amide functionality at the 1-position, and are useful as immune response modifiers, were prepared. Thus, reacting 2-(1H-imidazo[4,5-c]quinolin-1-yl)ethanol with 5-bromo-N-methyl-N-phenylpentamide followed by treatment of the resulting N-oxide product with trichloroacetyl isocyanate in CH₂Cl₂, and then treating the intermediate with NaOMe/MeOH afforded I [X = (CH₂)₂; R₁ = (CH₂)₄CONMePh; R₂ = H; n = 0] which showed interferon α induction at 3.33 μ M. The compds. I can induce the biosynthesis of various cytokines, and are useful in the treatment of a variety of conditions, including viral diseases and neoplastic diseases.

IT 436855-82-2P 436855-84-4P 436855-87-7P
 436855-91-3P 436855-95-7P 436855-97-9P
 436855-99-1P 436856-00-7P 436856-01-8P
 436856-02-9P 436856-03-0P 436856-04-1P
 436856-05-2P 436856-06-3P 436856-07-4P
 436856-08-5P 436856-09-6P 436856-10-9P
 436856-11-0P 436856-12-1P 436856-13-2P
 436856-14-3P 436856-15-4P 436856-16-5P
 436856-17-6P 436856-18-7P 436856-19-8P
 436856-42-7P 436856-44-9P 436856-46-1P
 436856-48-3P 436856-50-7P 436856-52-9P
 436856-54-1P 436856-56-3P 436856-58-5P


10681711

CN Pentanamide, 5-[2-(4-amino-1H-imidazo[4,5-c]quinolin-1-yl)ethoxy]-N-methyl-N-phenyl- (9CI) (CA INDEX NAME)




RN 436855-97-9 CAPLUS

CN Pentanamide, 5-[2-(4-amino-1H-imidazo[4,5-c]quinolin-1-yl)ethoxy]-N-butyl-N-phenyl- (9CI) (CA INDEX NAME)




RN 436855-99-1 CAPLUS

CN Acetic acid, [2-(4-amino-1H-imidazo[4,5-c]quinolin-1-yl)butoxy]-, methyl ester (9CI) (CA INDEX NAME)




RN 436856-00-7 CAPLUS



CN Cyclopropanecarboxamide, N-[2-[2-(4-amino-2-butyl-1H-imidazo[4,5-c]quinolin-1-yl)ethoxy]ethyl]- (9CI) (CA INDEX NAME)




RN 436856-01-8 CAPLUS
 CN Pentanamide, N-[2-[2-(4-amino-2-butyl-1H-imidazo[4,5-c]quinolin-1-yl)ethoxy]ethyl]- (9CI) (CA INDEX NAME)





RN 436856-02-9 CAPLUS
 CN Cyclopentanecarboxamide, N-[2-[2-(4-amino-2-butyl-1H-imidazo[4,5-c]quinolin-1-yl)ethoxy]ethyl]- (9CI) (CA INDEX NAME)



RN 436856-03-0 CAPLUS
 CN Benzamide, N-[2-[2-(4-amino-2-butyl-1H-imidazo[4,5-c]quinolin-1-yl)ethoxy]ethyl]- (9CI) (CA INDEX NAME)




RN 436856-04-1 CAPLUS
 CN Cyclohexanecarboxamide, N-[2-[2-(4-amino-2-butyl-1H-imidazo[4,5-c]quinolin-1-yl)ethoxy]ethyl]- (9CI) (CA INDEX NAME)





RN 436856-05-2 CAPLUS

CN Benzeneacetamide, N-[2-[2-(4-amino-2-butyl-1H-imidazo[4,5-c]quinolin-1-yl)ethoxy]ethyl]- (9CI) (CA INDEX NAME)





RN 436856-06-3 CAPLUS

CN Benzamide, N-[2-[2-(4-amino-2-butyl-1H-imidazo[4,5-c]quinolin-1-yl)ethoxy]ethyl]-4-fluoro- (9CI) (CA INDEX NAME)





RN 436856-07-4 CAPLUS
 CN 2-Thiopheneacetamide, N-[2-[2-(4-amino-2-butyl-1H-imidazo[4,5-c]quinolin-1-yl)ethoxy]ethyl]- (9CI) (CA INDEX NAME)







RN 436856-08-5 CAPLUS
 CN Benzamide, N-[2-[2-(4-amino-2-butyl-1H-imidazo[4,5-c]quinolin-1-yl)ethoxy]ethyl]-4-cyano- (9CI) (CA INDEX NAME)




RN 436856-09-6 CAPLUS
 CN Benzamide, N-[2-[2-(4-amino-2-butyl-1H-imidazo[4,5-c]quinolin-1-yl)ethoxy]ethyl]-3-cyano- (9CI) (CA INDEX NAME)





RN 436856-10-9 CAPLUS

CN Benzenepropanamide, N-[2-[2-(4-amino-2-butyl-1H-imidazo[4,5-c]quinolin-1-yl)ethoxy]ethyl]- (9CI) (CA INDEX NAME)





RN 436856-11-0 CAPLUS

CN Benzamide, N-[2-[2-(4-amino-2-butyl-1H-imidazo[4,5-c]quinolin-1-yl)ethoxy]ethyl]-3-methoxy- (9CI) (CA INDEX NAME)





RN 436856-12-1 CAPLUS
 CN Benzamide, N-[2-[2-(4-amino-2-butyl-1H-imidazo[4,5-c]quinolin-1-yl)ethoxy]ethyl]-4-methoxy- (9CI) (CA INDEX NAME)






RN 436856-13-2 CAPLUS
 CN 3-Pyridinecarboxamide, N-[2-[2-(4-amino-2-butyl-1H-imidazo[4,5-c]quinolin-1-yl)ethoxy]ethyl]-6-chloro- (9CI) (CA INDEX NAME)



RN 436856-14-3 CAPLUS
 CN Cyclopropanecarboxamide, N-[2-[2-(4-amino-2-butyl-1H-imidazo[4,5-c]quinolin-1-yl)ethoxy]ethyl]-2-phenyl-, (1R,2R)-rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.

10681711



RN 436856-15-4 CAPLUS


CN Acetamide, N-[2-[2-(4-amino-2-butyl-1H-imidazo[4,5-c]quinolin-1-yl)ethoxy]ethyl]-2-(phenylmethoxy)- (9CI) (CA INDEX NAME)




RN 436856-16-5 CAPLUS



CN 1-Naphthalenecarboxamide, N-[2-[2-(4-amino-2-butyl-1H-imidazo[4,5-c]quinolin-1-yl)ethoxy]ethyl]- (9CI) (CA INDEX NAME)

PAGE 1-A








RN 436856-17-6 CAPLUS
 CN Benzamide, N-[2-[2-(4-amino-2-butyl-1H-imidazo[4,5-c]quinolin-1-yl)ethoxy]ethyl]-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 436856-18-7 CAPLUS
 CN Benzamide, N-[2-[2-(4-amino-2-butyl-1H-imidazo[4,5-c]quinolin-1-yl)ethoxy]ethyl]-4-(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 436856-19-8 CAPLUS
 CN Benzamide, N-[2-[2-(4-amino-2-butyl-1H-imidazo[4,5-c]quinolin-1-yl)ethoxy]ethyl]-4-(trifluoromethoxy)- (9CI) (CA INDEX NAME)






RN 436856-42-7 CAPLUS


CN Pentanamide, N-[2-[2-(4-amino-1H-imidazo[4,5-c]quinolin-1-yl)ethoxy]ethyl]-
(9CI) (CA INDEX NAME)


RN 436856-44-9 CAPLUS

CN Benzamide, N-[2-[2-(4-amino-1H-imidazo[4,5-c]quinolin-1-yl)ethoxy]ethyl]-
(9CI) (CA INDEX NAME)

RN 436856-46-1 CAPLUS


CN Cyclohexanecarboxamide, N-[2-[2-(4-amino-1H-imidazo[4,5-c]quinolin-1-yl)ethoxy]ethyl]- (9CI) (CA INDEX NAME)







RN 436856-48-3 CAPLUS

CN Benzeneacetamide, N-[2-[2-(4-amino-1H-imidazo[4,5-c]quinolin-1-yl)ethoxy]ethyl]- (9CI) (CA INDEX NAME)



RN 436856-50-7 CAPLUS

CN 2-Thiopheneacetamide, N-[2-[2-(4-amino-1H-imidazo[4,5-c]quinolin-1-yl)ethoxy]ethyl]- (9CI) (CA INDEX NAME)




10681711


RN 436856-52-9 CAPLUS

CN Benzamide, N-[2-[2-(4-amino-1H-imidazo[4,5-c]quinolin-1-yl)ethoxy]ethyl]-4-cyano- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A





RN 436856-54-1 CAPLUS

CN Benzenepropanamide, N-[2-[2-(4-amino-1H-imidazo[4,5-c]quinolin-1-yl)ethoxy]ethyl]- (9CI) (CA INDEX NAME)




RN 436856-56-3 CAPLUS


CN Benzamide, N-[2-[2-(4-amino-1H-imidazo[4,5-c]quinolin-1-yl)ethoxy]ethyl]-3-methoxy- (9CI) (CA INDEX NAME)





RN 436856-58-5 CAPLUS

CN Benzamide, N-[2-[2-(4-amino-1H-imidazo[4,5-c]quinolin-1-yl)ethoxy]ethyl]-4-methoxy- (9CI) (CA INDEX NAME)






RN 436856-60-9 CAPLUS
 CN 3-Pyridinecarboxamide, N-[2-[2-(4-amino-1H-imidazo[4,5-c]quinolin-1-yl)ethoxy]ethyl]-6-chloro- (9CI) (CA INDEX NAME)




RN 436856-62-1 CAPLUS
 CN Acetamide, N-[2-[2-(4-amino-1H-imidazo[4,5-c]quinolin-1-yl)ethoxy]ethyl]-2-(phenylmethoxy)- (9CI) (CA INDEX NAME)



RN 436856-64-3 CAPLUS

10681711


CN 2-Naphthalenecarboxamide, N-[2-[2-(4-amino-1H-imidazo[4,5-c]quinolin-1-yl)ethoxy]ethyl]- (9CI) (CA INDEX NAME)




RN 436856-66-5 CAPLUS

CN Benzamide, N-[2-[2-(4-amino-1H-imidazo[4,5-c]quinolin-1-yl)ethoxy]ethyl]-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A




RN 436856-68-7 CAPLUS

CN Benzamide, N-[2-[2-(4-amino-1H-imidazo[4,5-c]quinolin-1-yl)ethoxy]ethyl]-4-


10681711

(trifluoromethyl)- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 436856-70-1 CAPLUS

CN Benzamide, N-[2-[2-(4-amino-1H-imidazo[4,5-c]quinolin-1-yl)ethoxy]ethyl]-4-(trifluoromethoxy)- (9CI) (CA INDEX NAME)

PAGE 1-A





IT 436856-84-7P 436856-92-7P 436856-98-3P


436857-12-4P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
(Reactant or reagent)

(preparation of amido ether substituted imidazoquinolines as immune response
modifiers)


RN 436856-84-7 CAPLUS

CN Carbamic acid, [2-[2-(4-amino-2-butyl-1H-imidazo[4,5-c]quinolin-1-yl)ethoxy]ethyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 436856-92-7 CAPLUS

CN Carbamic acid, [2-[2-(4-amino-1H-imidazo[4,5-c]quinolin-1-yl)ethoxy]ethyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 436856-98-3 CAPLUS


CN Carbamic acid, [2-[2-(4-amino-2-(2-methoxyethyl)-1H-imidazo[4,5-c]quinolin-1-yl)ethoxy]ethyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 436857-12-4 CAPLUS

CN Carbamic acid, [2-[2-(4-amino-2-(2-methoxyethyl)-1H-imidazo[4,5-c]quinolin-1-yl)ethoxy]ethyl]methyl-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

10681711



=>